ACTRN12605000043639尚未招募不适用
A randomised, placebo controlled, trial evaluating the impact of a routine daily interruption, versus adhoc interruption, to continuous infusion of sedatives in mechanically ventilated patients on length of mechanical ventilation and 6 month psychological outcome.
Department of Critical Care Medicine, Nepean Hospital.0 个研究点目标入组 80 人开始时间: 2005年7月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Predicted to require treatment via continuous infusion of sedation to tolerate mechanical ventilation for greater than 48 hours.
排除标准
- •Admitted for treatment of neurological or neurosurgical diagnosis. Under the care of a mental health team.
研究者
相似试验
已完成
3 期
Erythropoietin in Traumatic Brain Injury (EPO-TBI)ACTRN12609000827235Australian and New Zealand Intensive Care Research Centre606
进行中（未招募）
1 期
A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’sDisorderTourette’s DisorderMedDRA version: 20.0Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-002270-48-HUOtsuka Pharmaceutical Development & Commercialization, Inc.228
招募中
4 期
A randomised trial of krill oil for osteoarthritis of the kneeosteoarthritisACTRN12616000726459niversity of Tasmania260
招募中
2 期
Safety Assessment of Two Popular Legal Party Drugs: BZP and BZP+TFMPPSubjects who have used BZP or BZP+TFMPP on at least 3 previous occasionsOther -ACTRN12606000504516Ministry of Health New Zealand24
已完成
不适用
A randomized, placebo-controlled study to evaluate the effects of intravenous sevuparin on dermal and systemic LPS responses and the interaction between subcutaneous enoxaparin and sevuparin on coagulation responses in healthy volunteers.Septic shock10004018SepsisNL-OMON52250Modus therapeutics Inc.64